Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina. Greece.
Department of Internal Medicine, School of Medicine, University of Ioannina, 451 10 Ioannina. Greece.
Curr Vasc Pharmacol. 2017;15(6):566-575. doi: 10.2174/1570161115666170201105425.
Patients with diabetes usually exhibit diabetic dyslipidaemia.
The aim of the review is to present the quantitative and qualitative alterations of lipids and lipoproteins and the associated mechanisms in patients with diabetic dyslipidaemia.
The main quantitative changes observed in patients with diabetic dyslipidaemia are increased triglycerides and decreased high-density lipoprotein (HDL) cholesterol levels. Qualitative abnormalities mainly include increased small dense low-density lipoprotein (LDL) particles (despite similar serum LDL cholesterol levels as non-diabetic subjects) and alterations in the apolipoprotein content of HDL particles. Alterations in the activities of enzymes involved in lipoprotein metabolism, such as cholesteryl ester transfer protein, and the lipoprotein content of lipid particles, along with their glycation and oxidation, play a role in the pathogenesis of diabetic dyslipidaemia.
Diabetic dyslipidaemia is associated with quantitative and qualitative alterations of lipids and lipoproteins, which are associated with increased cardiovascular risk.
糖尿病患者通常表现出糖尿病脂代谢紊乱。
本综述旨在介绍糖尿病脂代谢紊乱患者的血脂和脂蛋白的定量和定性改变及其相关机制。
糖尿病脂代谢紊乱患者主要的定量变化是甘油三酯升高和高密度脂蛋白（HDL）胆固醇水平降低。定性异常主要包括小而密的低密度脂蛋白（LDL）颗粒增加（尽管血清 LDL 胆固醇水平与非糖尿病患者相似）和 HDL 颗粒载脂蛋白含量的改变。参与脂蛋白代谢的酶的活性改变，如胆固醇酯转移蛋白，以及脂蛋白的脂质含量及其糖化和氧化，在糖尿病脂代谢紊乱的发病机制中起作用。
糖尿病脂代谢紊乱与血脂和脂蛋白的定量和定性改变有关，这与心血管风险增加有关。
